90 percent of HCV sufferers to be treated with triple therapy regimens.

These doctors indicate that they can likely make use of Pegasys in triple therapy regimens as nearly all HCV-specific antiviral brokers are being evaluated with Pegasys rather than PegIntron.S. Study of 74 gastroenterologists, 26 hepatologists and 20 MCO pharmacy directors. Their responses were in comparison to assess similarities and variations of opinion regarding scientific, economic and scientific factors.. 90 percent of HCV sufferers to be treated with triple therapy regimens, finds Decision Resources Decision Resources, one of the world’s leading study and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical profiles provided to them, surveyed clinicians estimate that one year after the launch of Vertex Pharmaceuticals/Johnson & Johnson/Mitsubishi Tanabe Pharma’s telaprevir and Merck’s boceprevir, in least 90 % of hepatitis C virus patients will end up being treated with triple therapy regimens.Marco Gerlinger, M.D., Andrew J. Rowan, B.Sc., Stuart Horswell, M.Math., James Larkin, M.D., Ph.D., David Endesfelder, Dip.Mathematics., Eva Gronroos, Ph.D., Pierre Martinez, Ph.D., Nicholas Matthews, B.Sc., Aengus Stewart, M.Sc., Patrick Tarpey, Ph.D., Ignacio Varela, Ph.D., Benjamin Phillimore, B.Sc., Sharmin Begum, M.Sc., Neil Q. McDonald, Ph.D., Adam Butler, B.Sc., David Jones, M.Sc., Keiran Raine, M.Sc., Calli Latimer, B.Sc., Claudio R. Santos, Ph.D., Mahrokh Nohadani, H.N.C., Aron C. Eklund, Ph.D., Bradley Spencer-Dene, Ph.D., Graham Clark, B.Sc., Lisa Pickering, M.D., Ph.D., Gordon Stamp, M.D., Martin Gore, M.D., Ph.D., Zoltan Szallasi, M.D., Julian Downward, Ph.D., P.